Roivant Sciences (ROIV) Change in Account Payables (2020 - 2026)
Roivant Sciences' (ROIV) quarterly Change in Account Payables came in at -$12.7 million in Q4 2025, up 29.25% YoY from -$9.9 million in Q4 2024, and down 525.13% on a QoQ basis from $3.0 million in Q3 2025.
Roivant Sciences (ROIV) Change in Account Payables (2020 - 2026) Analysis & Trends
Roivant Sciences (ROIV) has 6 years of Change in Account Payables data on file, last reported at -$12.7 million in Q4 2025.
- Quarterly Change in Account Payables rose 29.25% year-over-year to -$12.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$39.5 million (down 15.25% YoY) and the FY2026 annual result came in at $3.4 million, up 118.81% from the prior year.
- Change in Account Payables slipped to -$12.7 million in Q4 2025, from $3.0 million in the prior quarter.
- In the past five years, Change in Account Payables ranged from a high of $62.9 million in Q3 2021 to a low of -$25.3 million in Q2 2024.
- A 5-year average of $2.4 million and a median of $1.8 million in 2023 frame the typical range for Change in Account Payables.
- The widest YoY moves for Change in Account Payables: up 501.0% in 2024, down 1101.84% in 2024.
- Tracing ROIV's Change in Account Payables over 5 years: stood at $3.7 million in 2021, then soared by 278.28% to $14.0 million in 2022, then tumbled by 87.14% to $1.8 million in 2023, then slumped by 1101.84% to -$18.0 million in 2024, then increased by 29.25% to -$12.7 million in 2025.
- The last three Change in Account Payables figures came in at -$12.7 million (Q4 2025), $3.0 million (Q3 2025), and -$11.7 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 5.03 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 37.53 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 520,137.79 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 7.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.11 Mn |
| Jun 30, 2026 | 7.11 Mn |
| Dec 31, 2025 | -12.74 Mn |
| Dec 31, 2025 | -12.74 Mn |
| Sep 30, 2025 | 3.00 Mn |
| Sep 30, 2025 | 3.00 Mn |
| Jun 30, 2025 | -11.75 Mn |
| Jun 30, 2025 | -11.75 Mn |
| Dec 31, 2024 | -18.00 Mn |
| Dec 31, 2024 | -18.00 Mn |
| Sep 30, 2024 | 7.21 Mn |
| Sep 30, 2024 | 7.21 Mn |
| Jun 30, 2024 | -25.27 Mn |
| Jun 30, 2024 | -25.27 Mn |
| Dec 31, 2023 | 1.80 Mn |
| Dec 31, 2023 | 1.80 Mn |
| Sep 30, 2023 | -1.80 Mn |
| Sep 30, 2023 | -1.80 Mn |
| Jun 30, 2023 | 11.94 Mn |
| Jun 30, 2023 | 11.94 Mn |